BioMedNewsBreaks

FridaySep 29, 2023 2:00 pm

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked a deal with GEDi Cube Intl Ltd. The agreement is to combine the two companies with GEDi Cube becoming a wholly owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company would focus on accelerating precision and personalized medicine for longevity powered by mutually reinforcing artificial intelligence (“AI”) and biotechnology platforms to enable early diagnosis, better targeted treatments and drug discovery. GEDi Cube is an artificial intelligence medical technology company. According…

Continue Reading

ThursdaySep 28, 2023 1:26 pm

BioMedNewsBreaks — SenesTech Inc. (NASDAQ: SNES) Partners with IBN for Corporate Communications Initiatives

SenesTech (NASDAQ: SNES), animal pest fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. According to the announcement, IBN will leverage its suite of communications solutions to generate greater awareness of SenesTech, a company focused on developing effective pest-control solutions that are grounded in science and proven through field testing. IBN brings an array of communication channels to the new partnership, including an investor-based distribution network of more than 5,000 key syndication outlets,…

Continue Reading

ThursdaySep 28, 2023 11:51 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the…

Continue Reading

WednesdaySep 27, 2023 11:54 am

BioMedNewsBreaks – CSurgeries, Sheltowee Network Partner to Relaunch Platform, Revolutionize Surgical Training

CSurgeries, a top-tier online surgical video journal, is collaborating with Sheltowee Network, a leading innovation commercialization company. According to the announcement, the two companies will work together to make high-quality, peer-reviewed surgical content more accessible for medical professionals and students around the world. CSurgeries is redesigning its platform to add new features as well as an invaluable library of surgical videos; the company is also focused on strengthening key industry partnerships. The company will work with Sheltowee Network, which has built a reputation for magnifying business opportunities and catalyzing growth across various sectors through strategic investment of monetary capital and…

Continue Reading

TuesdaySep 26, 2023 12:56 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces Acquisition of World-Class Gene-Editing Platform

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.) According to the announcement, ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome.…

Continue Reading

TuesdaySep 26, 2023 12:48 pm

BioMedNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Board Appointment of the Honorable Jack Brewer, M.Ed.

Safety Shot (NASDAQ: SHOT) today announced that Jack Brewer, M.Ed. has joined the company’s advisory board. Brewer is an ordained minister who possesses a unique combination of expertise in the fields of global economic development, sports and finance through his roles as a successful entrepreneur, executive producer, news contributor and humanitarian. He currently serves as CEO and portfolio manager of The Brewer Group Inc., White House appointee on the U.S. Commission for the Social Status of Black Men & Boys, chair at the America First Policy Institute’s Center for Opportunity Now, as well as well as the founder and executive…

Continue Reading

TuesdaySep 26, 2023 12:39 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and Pooja Chatterjee will be vice president over clinical. The two positions are designed to support clinical development and commercialization of HeartBeam’s ambulatory VECG products. With more than 13 years of experience collecting market-level insights and translating those insights into business needs, Gujarati has an impressive…

Continue Reading

FridaySep 22, 2023 2:43 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Making Significant Strides to Advance Cellular Therapy Programs

Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty. “The company is guided by the mission to advance cell-based product candidates into pivotal phase 3 trials, with the goal of attaining regulatory approvals and subsequently commercializing the product. Longeveron has so far made significant strides in line with this mission,” reads a recent article that discussed attendance by the company’s CEO Wa’el Hashad and EVP and CFO Lisa Locklear at the recent 25th Annual H.C. Wainwright Global Investment Conference. At the…

Continue Reading

FridaySep 22, 2023 1:59 pm

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Anticipating Growing Demand for UPNEEQ(R)

RVL Pharmaceuticals (NASDAQ: RVLP) is a a specialty pharmaceutical company whose near-term focus is to continue the rollout of UPNEEQ(R) into the medical aesthetics market through its dedicated sales force. “UPNEEQ(R) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis… UPNEEQ(R), the first and only FDA-approved eye drop for low-lying eyelids, fits into the non-invasive medical aesthetics category. With a single drop per day, clinical trials showed an average of one-millimeter lift to the upper eyelid, improving appearance and the superior visual field in patients with a functional deficit. Testing also…

Continue Reading

FridaySep 22, 2023 1:50 pm

BioMedNewsBreaks — SOHM Inc. (SHMN) Expands Team to Direct Global Growth Strategy

SOHM (OTC: SHMN) is a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories. “SOHM is strengthening its governing team with the addition of two experienced visionaries committed to helping the company’s growth in the pharmaceutical, nutraceutical and cosmeceutical marketplace… The new officers are expected to help direct SOHM’s global growth strategy as the company continues to develop and diversify its product offerings, which include a variety of mediums for administering antibiotics, analgesics, anti-inflammatory and anti-cold therapies, as well as vitamins,” a recent article reads. “Dr. Krishna Bhat, MD, Ph.D, FACC, an experienced bioscientist…

Continue Reading